Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy

1.

Roy DG, Kaymak I, Williams KS, Ma EH, Jones RG. Immunometabolism in the tumor microenvironment. Ann Rev Cancer Biol. 2021;5:137–59. https://doi.org/10.1146/annurev-cancerbio-030518-055817.CrossRef

2.

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37. https://doi.org/10.1038/nm.3394.CrossRefPubMedPubMedCentral

3.

Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101:147–76. https://doi.org/10.1152/physrev.00048.2019.CrossRefPubMed

4.

Eggert T, Greten TF. Tumor regulation of the tissue environment in the liver. Pharmacol Ther. 2017;173:47–57. https://doi.org/10.1016/j.pharmthera.2017.02.005.CrossRefPubMedPubMedCentral

5.

Germic N, Frangez Z, Yousefi S, Simon HU. Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation. Cell Death Differ. 2019;26:715–27. https://doi.org/10.1038/s41418-019-0297-6.CrossRefPubMedPubMedCentral

6.

Gaber T, Strehl C, Buttgereit F. Metabolic regulation of inflammation. Nat Rev Rheumatol. 2017;13:267–79. https://doi.org/10.1038/nrrheum.2017.37.CrossRefPubMed

7.

Geltink RIK, Kyle RL, Pearce EL. Unraveling the complex interplay between T cell metabolism and function. Annu Rev Immunol. 2018;36:461–88. https://doi.org/10.1146/annurev-immunol-042617-053019.CrossRefPubMed

8.

Wu Q, Yu X, Li J, Sun S, Tu Y. Metabolic regulation in the immune response to cancer. Cancer Commun (Lond). 2021;41:661–94. https://doi.org/10.1002/cac2.12182.CrossRefPubMed

9.

Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17:351–9. https://doi.org/10.1038/ncb3124.CrossRefPubMedPubMedCentral

10.

Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18:744–57. https://doi.org/10.1038/s41568-018-0074-8.CrossRefPubMed

11.

Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21:183–203. https://doi.org/10.1038/s41580-019-0199-y.CrossRefPubMedPubMedCentral

12.

Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013;15:555–64. https://doi.org/10.1038/ncb2763.CrossRefPubMedPubMedCentral

13.

Blommaart EF, Luiken JJ, Blommaart PJ, van Woerkom GM, Meijer AJ. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem. 1995;270:2320–6. https://doi.org/10.1074/jbc.270.5.2320.CrossRefPubMed

14.

Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019;21:63–71. https://doi.org/10.1038/s41556-018-0205-1.CrossRefPubMed

15.

Li Y. Lipid metabolism in tumor immunity, vol. 1316. Singapore: Springer; 2021.

16.

Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169:570–86. https://doi.org/10.1016/j.cell.2017.04.004.CrossRefPubMedPubMedCentral

17.

Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2:251–62. https://doi.org/10.1038/nri778.CrossRefPubMed

18.

Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol. 2004;16:89–98. https://doi.org/10.1016/j.smim.2003.12.005.CrossRefPubMed

19.

Bennett CL, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–1. https://doi.org/10.1038/83713.CrossRefPubMed

20.

Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6. https://doi.org/10.1038/ni904.CrossRefPubMed

21.

Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19:116. https://doi.org/10.1186/s12943-020-01234-1.CrossRefPubMedPubMedCentral

22.

Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109–18. https://doi.org/10.1038/cr.2016.151.CrossRefPubMed

23.

Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356–71. https://doi.org/10.1038/s41571-019-0175-7.CrossRefPubMed

24.

Joseph Louis Proust WJ. Revista CENIC. Ciencias Químicas. 2012;43.

25.

Ehrlich F. Ueber das natürliche Isomere des Leucins. Ber Dtsch Chem Ges. 1904;37:1809–40. https://doi.org/10.1002/cber.19040370295.CrossRef

26.

Fischer E. Ueber eine neue Aminosäure aus Leim. Ber Dtsch Chem Ges. 1902;35:2660–5. https://doi.org/10.1002/cber.19020350324.CrossRef

27.

Passlack N, Doherr MG, Zentek J. Effects of free amino acids on cytokine secretion and proliferative activity of feline T cells in an in vitro study using the cell line MYA-1. Cytotechnology. 2016;68:1949–61. https://doi.org/10.1007/s10616-016-0008-9.CrossRefPubMedPubMedCentral

28.

Sun Y, et al. Gentamicin induced microbiome adaptations associate with increased BCAA levels and enhance severity of influenza infection. Front Immunol. 2020;11:608895. https://doi.org/10.3389/fimmu.2020.608895.CrossRefPubMed

29.

Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34:139–58. https://doi.org/10.1016/j.mam.2012.10.007.CrossRefPubMed

30.

Lee Y, et al. Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc. Nat Struct Mol Biol. 2019;26:510–7. https://doi.org/10.1038/s41594-019-0237-7.CrossRefPubMed

31.

Yan R, Zhao X, Lei J, Zhou Q. Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex. Nature. 2019;568:127–30. https://doi.org/10.1038/s41586-019-1011-z.CrossRefPubMed

32.

Sinclair LV, et al. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol. 2013;14:500–8. https://doi.org/10.1038/ni.2556.CrossRefPubMedPubMedCentral

33.

Nicklin P, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136:521–34. https://doi.org/10.1016/j.cell.2008.11.044.CrossRefPubMedPubMedCentral

34.

Najumudeen AK, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat Genet. 2021;53:16–26. https://doi.org/10.1038/s41588-020-00753-3.CrossRefPubMed

35.

Cormerais Y, et al. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5). J Biol Chem. 2018;293:2877–87. https://doi.org/10.1074/jbc.RA117.001342.CrossRefPubMedPubMedCentral

36.

Ichihara A, Koyama E. Transaminase of branched chain amino acids. I. Branched chain amino acids-alpha-ketoglutarate transaminase. J Biochem. 1966;59:160–9. https://doi.org/10.1093/oxfordjournals.jbchem.a128277.CrossRefPubMed

37.

Taylor RT, Jenkins WT. Leucine aminotransferase. J Biol Chem. 1966;241:4396–405. https://doi.org/10.1016/S0021-9258(18)99734-6S1-10M4-Citavi.CrossRefPubMed

38.

Nunes EA, et al. β-Hydroxy-β-methylbutyrate modifies human peripheral blood mononuclear cell proliferation and cytokine production in vitro. Nutrition (Burbank, Los Angeles County, Calif). 2011;27:92–9. https://doi.org/10.1016/j.nut.2009.12.008.CrossRefPubMed

39.

Taheri F, et al. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin Cancer Res. 2001;7:958s–65s.PubMed

40.

Rodriguez PC, et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem. 2002;277:21123–9. https://doi.org/10.1074/jbc.M110675200.CrossRefPubMed

41.

Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012;12:325–38. https://doi.org/10.1038/nri3198.CrossRefPubMedPubMedCentral

42.

Myers DR, Wheeler B, Roose JP. mTOR and other effector kinase signals that impact T cell function and activity. Immunol Rev. 2019;291:134–53. https://doi.org/10.1111/imr.12796.CrossRefPubMedPubMedCentral

43.

Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity. 2010;33:301–11. https://doi.org/10.1016/j.immuni.2010.09.002.CrossRefPubMedPubMedCentral

44.

Ananieva EA, Patel CH, Drake CH, Powell JD, Hutson SM. Cytosolic branched chain aminotransferase (BCATc) regulates mTORC1 signaling and glycolytic metabolism in CD4+ T cells. J Biol Chem. 2014;289:18793–804. https://doi.org/10.1074/jbc.M114.554113.CrossRefPubMedPubMedCentral

45.

Wolfson RL, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science (New York, NY). 2016;351:43–8. https://doi.org/10.1126/science.aab2674.CrossRefPubMed

46.

Chen J, et al. SAR1B senses leucine levels to regulate mTORC1 signalling. Nature. 2021. https://doi.org/10.1038/s41586-021-03768-w.CrossRefPubMedPubMedCentral

47.

Vallion R, et al. Regulatory T cell stability and migration are dependent on mTOR. J Immunol (Baltimore, Md 1950). 2020;205:1799–809. https://doi.org/10.4049/jimmunol.1901480.CrossRef

48.

Shi H, et al. Amino acids license kinase mTORC1 activity and treg cell function via small G proteins Rag and Rheb. Immunity. 2019;51:1012-1027.e1017. https://doi.org/10.1016/j.immuni.2019.10.001.CrossRefPubMedPubMedCentral

49.

Zeng H, et al. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. Nature. 2013;499:485–90. https://doi.org/10.1038/nature12297S1-7M4-Citavi.CrossRefPubMedPubMedCentral

50.

Kato H, Perl A. Blockade of treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:427–38. https://doi.org/10.1002/art.40380.CrossRefPubMedPubMedCentral

51.

Hattori A, et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature. 2017;545:500–4. https://doi.org/10.1038/nature22314.CrossRefPubMedPubMedCentral

52.

Sunyer R, et al. Collective cell durotaxis emerges from long-range intercellular force transmission. Science (New York, NY). 2016;353:1157–61. https://doi.org/10.1126/science.aaf7119.CrossRefPubMed

53.

Martin SB, et al. Leucine and branched-chain amino acid metabolism contribute to the growth of bone sarcomas by regulating AMPK and mTORC1 signaling. Biochem J. 2020;477:1579–99. https://doi.org/10.1042/BCJ20190754.CrossRefPubMed

54.

Ericksen RE, et al. Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression. Cell Metab. 2019;29:1151-1165.e1156. https://doi.org/10.1016/j.cmet.2018.12.020.CrossRefPubMedPubMedCentral

55.

Lei M-Z, et al. Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. Signal Transduct Target Ther. 2020;5:70. https://doi.org/10.1038/s41392-020-0168-0.CrossRefPubMedPubMedCentral

56.

Li J-T, et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat Cell Biol. 2020;22:167–74. https://doi.org/10.1038/s41556-019-0455-6.CrossRefPubMed

57.

Tian Q, et al. Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer. Oncogene. 2020;39:3980–96. https://doi.org/10.1038/s41388-020-1262-z.CrossRefPubMedPubMedCentral

58.

Krebs HA. Metabolism of amino-acids: the synthesis of glutamine from glutamic acid and ammonia, and the enzymic hydrolysis of glutamine in animal tissues. Biochem J. 1935;29:1951–69. https://doi.org/10.1042/bj0291951.CrossRefPubMedPubMedCentral

59.

Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619–34. https://doi.org/10.1038/nrc.2016.71.CrossRefPubMedPubMedCentral

60.

Song M, et al. IRE1alpha-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. 2018;562:423–8. https://doi.org/10.1038/s41586-018-0597-x.CrossRefPubMedPubMedCentral

61.

Huang H, et al. In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8(+) T cell fate decisions. Cell. 2021;184:1245–61. https://doi.org/10.1016/j.cell.2021.02.021.CrossRefPubMedPubMedCentral

62.

Procaccini C, et al. Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. Immunity. 2021;54:1543–60. https://doi.org/10.1016/j.immuni.2021.04.014.CrossRefPubMed

63.

Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599–620. https://doi.org/10.1007/s13238-020-00789-5.CrossRefPubMed

64.

Swamy M, et al. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat Immunol. 2016;17:712–20. https://doi.org/10.1038/ni.3439.CrossRefPubMedPubMedCentral

65.

Blagih J, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity. 2015;42:41–54. https://doi.org/10.1016/j.immuni.2014.12.030.CrossRefPubMed

66.

Lian G, et al. Glutathione de novo synthesis but not recycling process coordinates with glutamine catabolism to control redox homeostasis and directs murine T cell differentiation. Elife. 2018. https://doi.org/10.7554/eLife.36158.CrossRefPubMedPubMedCentral

67.

Johnson MO, et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell. 2018;175:1780-1795.e1719. https://doi.org/10.1016/j.cell.2018.10.001.CrossRefPubMedPubMedCentral

68.

Klysz D, et al. Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal. 2015;8:ra97. https://doi.org/10.1126/scisignal.aab2610.CrossRefPubMed

69.

Leone RD, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science (New York, NY). 2019;366:1013–21. https://doi.org/10.1126/science.aav2588.CrossRefPubMed

70.

Hopkins FG, Cole SW. A contribution to the chemistry of proteids: Part I. A preliminary study of a hitherto undescribed product of tryptic digestion. J Physiol. 1901;27:418–28. https://doi.org/10.1113/jphysiol.1901.sp000880.CrossRefPubMedPubMedCentral

71.

Hopkins FG. Feeding experiments illustrating the importance of accessory factors in normal dietaries. J Physiol. 1912;44:425–60. https://doi.org/10.1113/jphysiol.1912.sp001524.CrossRefPubMedPubMedCentral

72.

Platten M, Nollen EAA, Rohrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18:379–401. https://doi.org/10.1038/s41573-019-0016-5.CrossRefPubMed

73.

Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017. https://doi.org/10.1126/science.aaf9794.CrossRefPubMed

74.

Du L, et al. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway. Signal Transduct Target Ther. 2020;5:10. https://doi.org/10.1038/s41392-019-0103-4.CrossRefPubMedPubMedCentral

75.

Mellor AL, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol. 2001;2:64–8. https://doi.org/10.1038/83183.CrossRefPubMed

76.

Bauer TM, et al. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int. 2005;18:95–100. https://doi.org/10.1111/j.1432-2277.2004.00031.x.CrossRefPubMed

77.

Hainz U, et al. Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation. Blood. 2005;105:4127–34. https://doi.org/10.1182/blood-2004-05-1726.CrossRefPubMedPubMedCentral

78.

Byakwaga H, et al. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014;210:383–91. https://doi.org/10.1093/infdis/jiu115.CrossRefPubMedPubMedCentral

79.

Dai X, Zhu BT. Suppression of T-cell response and prolongation of allograft survival in a rat model by tryptophan catabolites. Eur J Pharmacol. 2009;606:225–32. https://doi.org/10.1016/j.ejphar.2008.12.053.CrossRefPubMed

80.

Frumento G, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196:459–68. https://doi.org/10.1084/jem.20020121.CrossRefPubMedPubMedCentral

81.

Kudo Y, Boyd CA. Characterisation of L-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles. J Physiol. 2001;531:405–16. https://doi.org/10.1111/j.1469-7793.2001.0405i.x.CrossRefPubMedPubMedCentral

82.

Liu Y, et al. Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation. Cancer Cell. 2018;33:480–94. https://doi.org/10.1016/j.ccell.2018.02.005.CrossRefPubMed

83.

Silk JD, et al. IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells. J Immunol (Baltimore, Md: 1950). 2011;187:1617–25. https://doi.org/10.4049/jimmunol.1000815.CrossRef

84.

Harding HP, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6:1099–108. https://doi.org/10.1016/s1097-2765(00)00108-8M4-Citavi.CrossRefPubMed

85.

Munn DH, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633–42. https://doi.org/10.1016/j.immuni.2005.03.013.CrossRefPubMed

86.

Keil M, et al. General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. J Neuroimmunol. 2016;297:117–26. https://doi.org/10.1016/j.jneuroim.2016.05.014.CrossRefPubMed

87.

Wang P, et al. The amino acid sensor general control nonderepressible 2 (GCN2) controls TH9 cells and allergic airway inflammation. J Allergy Clin Immunol. 2019;144:1091–105. https://doi.org/10.1016/j.jaci.2019.04.028.CrossRefPubMed

88.

Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I. Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells. Immunology. 2015;146:292–300. https://doi.org/10.1111/imm.12502.CrossRefPubMedPubMedCentral

89.

van de Velde L-A, et al. Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing. Cell Rep. 2016;17:2247–58. https://doi.org/10.1016/j.celrep.2016.10.079.CrossRefPubMedPubMedCentral

90.

Rashidi A, et al. GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma. Cancer Immunol Immunother CII. 2020;69:81–94. https://doi.org/10.1007/s00262-019-02441-6.CrossRefPubMed

91.

Sonner JK, et al. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. Oncoimmunology. 2016;5:e1240858. https://doi.org/10.1080/2162402X.2016.1240858.CrossRefPubMedPubMedCentral

92.

Fallarino F, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176:6752–61. https://doi.org/10.4049/jimmunol.176.11.6752.CrossRefPubMed

93.

Mezrich JD, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (Baltimore, Md:1950). 2010;185:3190–8. https://doi.org/10.4049/jimmunol.0903670.CrossRef

94.

Sinclair LV, Neyens D, Ramsay G, Taylor PM, Cantrell DA. Single cell analysis of kynurenine and system L amino acid transport in T cells. Nat Commun. 2018;9:1981. https://doi.org/10.1038/s41467-018-04366-7.CrossRefPubMedPubMedCentral

95.

Campesato LF, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020;11:4011. https://doi.org/10.1038/s41467-020-17750-z.CrossRefPubMedPubMedCentral

96.

Quintana FJ, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65–71. https://doi.org/10.1038/nature06880.CrossRefPubMed

97.

Mueller JH. A new sulfur-containing amino-acid isolated from the hydrolytic products of protein. J Biol Chem. 1923;56:157–69.CrossRef

98.

Odake S. On the occurrence of a sulphur-containing amino acid in yeast. J Agric Chem Soc Jpn. 1925;1:601–9.

99.

Barger G, Coyne FP. The amino-acid methionine; constitution and synthesis. Biochem J. 1928;22:1417–25. https://doi.org/10.1042/bj0221417.CrossRefPubMedPubMedCentral

100.

Sanderson SM, Gao X, Dai Z, Locasale JW. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat Rev Cancer. 2019;19:625–37. https://doi.org/10.1038/s41568-019-0187-8.CrossRefPubMed

101.

Hine C, et al. Endogenous hydrogen sulfide production is essential for dietary restriction benefits. Cell. 2015;160:132–44. https://doi.org/10.1016/j.cell.2014.11.048.CrossRefPubMed

102.

Sutter BM, Wu X, Laxman S, Tu BP. Methionine inhibits autophagy and promotes growth by inducing the SAM-responsive methylation of PP2A. Cell. 2013;154:403–15. https://doi.org/10.1016/j.cell.2013.06.041.CrossRefPubMedPubMedCentral

103.

Sinclair LV, et al. Antigen receptor control of methionine metabolism in T cells. Elife. 2019. https://doi.org/10.7554/eLife.44210.CrossRefPubMedPubMedCentral

104.

Bian Y, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585:277–82. https://doi.org/10.1038/s41586-020-2682-1.CrossRefPubMedPubMedCentral

105.

Roy DG, et al. Methionine metabolism shapes T helper cell responses through regulation of epigenetic reprogramming. Cell Metab. 2020;31:250-266.e259. https://doi.org/10.1016/j.cmet.2020.01.006.CrossRefPubMed

106.

Dai Z, Mentch SJ, Gao X, Nichenametla SN, Locasale JW. Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun. 2018;9:1955. https://doi.org/10.1038/s41467-018-04426-y.CrossRefPubMedPubMedCentral

107.

Hung MH, et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat Commun. 2021;12:1455. https://doi.org/10.1038/s41467-021-21804-1.CrossRefPubMedPubMedCentral

108.

Saini N, et al. Methionine uptake via the SLC43A2 transporter is essential for regulatory T-cell survival. Life Sci Alliance. 2022;10:15. https://doi.org/10.26508/lsa.202201663.CrossRef

109.

Schulze E, Steiger E. Ueber das Arginin. Z für Physiol Chem 11.

110.

Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641–54. https://doi.org/10.1038/nri1668.CrossRefPubMed

111.

Zhu X, et al. The central role of arginine catabolism in T-cell dysfunction and increased susceptibility to infection after physical injury. Ann Surg. 2014;259:171–8. https://doi.org/10.1097/SLA.0b013e31828611f8.CrossRefPubMed

112.

Bernard A, et al. Red blood cell arginase suppresses Jurkat (T cell) proliferation by depleting arginine. Surgery. 2008;143:286–91. https://doi.org/10.1016/j.surg.2007.07.037.CrossRefPubMed

113.

Stadelmann B, Hanevik K, Andersson MK, Bruserud O, Svard SG. The role of arginine and arginine-metabolizing enzymes during Giardia—host cell interactions in vitro. BMC Microbiol. 2013;13:256. https://doi.org/10.1186/1471-2180-13-256.CrossRefPubMedPubMedCentral

114.

Modolell M, et al. Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis. 2009;3:e480. https://doi.org/10.1371/journal.pntd.0000480.CrossRefPubMedPubMedCentral

115.

Yeh CL, et al. Intravenous arginine administration benefits CD4(+) T-cell homeostasis and attenuates liver inflammation in mice with polymicrobial sepsis. Nutrients. 2020. https://doi.org/10.3390/nu12041047.CrossRefPubMedPubMedCentral

116.

Zea AH, et al. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 2004;232:21–31. https://doi.org/10.1016/j.cellimm.2005.01.004.CrossRefPubMed

117.

Yu HR, et al. The functional DNA methylation signatures relevant to altered immune response of neonatal T cells with l-arginine supplementation. Nutrients. 2021. https://doi.org/10.3390/nu13082780.CrossRefPubMedPubMedCentral

118.

Werner A, et al. Induced arginine transport via cationic amino acid transporter-1 is necessary for human T-cell proliferation. Eur J Immunol. 2016;46:92–103. https://doi.org/10.1002/eji.201546047.CrossRefPubMed

119.

Huang Y, et al. The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway. J Neurosci Off J Soc Neurosci. 2007;27:449–58. https://doi.org/10.1523/JNEUROSCI.4489-06.2007.CrossRef

120.

Jungnickel KEJ, Parker JL, Newstead S. Structural basis for amino acid transport by the CAT family of SLC7 transporters. Nat Commun. 2018;9:550. https://doi.org/10.1038/s41467-018-03066-6.CrossRefPubMedPubMedCentral

121.

Wang S, et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science (New York, NY). 2015;347:188–94. https://doi.org/10.1126/science.1257132.CrossRefPubMed

122.

Rebsamen M, et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature. 2015;519:477–81. https://doi.org/10.1038/nature14107.CrossRefPubMedPubMedCentral

123.

Wyant GA, et al. mTORC1 activator SLC38A9 is required to efflux essential amino acids from lysosomes and use protein as a nutrient. Cell. 2017;171:642-654.e612. https://doi.org/10.1016/j.cell.2017.09.046.CrossRefPubMedPubMedCentral

124.

Saxton RA, Chantranupong L, Knockenhauer KE, Schwartz TU, Sabatini DM. Mechanism of arginine sensing by CASTOR1 upstream of mTORC1. Nature. 2016;536:229–33. https://doi.org/10.1038/nature19079.CrossRefPubMedPubMedCentral

125.

Jung J, Genau HM, Behrends C. Amino acid-dependent mTORC1 regulation by the lysosomal membrane protein SLC38A9. Mol Cell Biol. 2015;35:2479–94. https://doi.org/10.1128/MCB.00125-15.CrossRefPubMedPubMedCentral

126.

Chantranupong L, et al. The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell. 2016;165:153–64. https://doi.org/10.1016/j.cell.2016.02.035.CrossRefPubMedPubMedCentral

127.

Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109:1568–73. https://doi.org/10.1182/blood-2006-06-031856.CrossRefPubMedPubMedCentral

128.

Rodriguez PC, et al. L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol. 2010;185:5198–204. https://doi.org/10.4049/jimmunol.1001224.CrossRefPubMed

129.

van de Velde L-A, et al. T cells encountering myeloid cells programmed for amino acid-dependent immunosuppression use rictor/mTORC2 protein for proliferative checkpoint decisions. J Biol Chem. 2017;292:15–30. https://doi.org/10.1074/jbc.M116.766238.CrossRefPubMed

130.

Fultang L, et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood. 2020;136:1155–60. https://doi.org/10.1182/blood.2019004500.CrossRefPubMedPubMedCentral

131.

Wu G, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336(Pt 1):1–17. https://doi.org/10.1042/bj3360001.CrossRefPubMedPubMedCentral

132.

Werner A, et al. Reconstitution of T cell proliferation under arginine limitation: activated human T cells take up citrulline via L-type amino acid transporter 1 and use it to regenerate arginine after induction of argininosuccinate synthase expression. Front Immunol. 2017;8:864. https://doi.org/10.3389/fimmu.2017.00864.CrossRefPubMedPubMedCentral

133.

Chapman NM, et al. mTOR coordinates transcriptional programs and mitochondrial metabolism of activated Treg subsets to protect tissue homeostasis. Nat Commun. 2018;9:2095. https://doi.org/10.1038/s41467-018-04392-5.CrossRefPubMedPubMedCentral

134.

Gerriets VA, et al. Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol. 2016;17:1459–66. https://doi.org/10.1038/ni.3577.CrossRefPubMedPubMedCentral

135.

Fletcher M, et al. l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Can Res. 2015;75:275–83. https://doi.org/10.1158/0008-5472.CAN-14-1491.CrossRef

136.

Marti Líndez A-A, et al. Mitochondrial arginase-2 is a cell-autonomous regulator of CD8+ T cell function and antitumor efficacy. JCI Insight. 2019. https://doi.org/10.1172/jci.insight.132975.CrossRef

137.

Geiger R, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167:829-842.e813. https://doi.org/10.1016/j.cell.2016.09.031.CrossRefPubMedPubMedCentral

138.

Cramer E, Almén A, Ruge E. Mittheilungen aus dem analytischen Laboratorium in Zürich. I. Beiträge zur Kenntniss der Anilinfarbstoffe. J für Prakt Chem. 1865;96:65–140. https://doi.org/10.1002/prac.18650960111.CrossRef

139.

El-Hattab AW. Serine biosynthesis and transport defects. Mol Genet Metab. 2016;118:153–9. https://doi.org/10.1016/j.ymgme.2016.04.010.CrossRefPubMed

140.

Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin Cancer Biol. 2005;15:254–66. https://doi.org/10.1016/j.semcancer.2005.04.005.CrossRefPubMed

141.

Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016;16:650–62. https://doi.org/10.1038/nrc.2016.81.CrossRefPubMed

142.

Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab. 2017;25:27–42. https://doi.org/10.1016/j.cmet.2016.08.009.CrossRefPubMed

143.

Ma EH, et al. Serine is an essential metabolite for effector T cell expansion. Cell Metab. 2017;25:345–57. https://doi.org/10.1016/j.cmet.2016.12.011.CrossRefPubMed

144.

Ron-Harel N, et al. Mitochondrial biogenesis and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab. 2016;24:104–17. https://doi.org/10.1016/j.cmet.2016.06.007.CrossRefPubMedPubMedCentral

145.

Kurniawan H, et al. Glutathione restricts serine metabolism to preserve regulatory T cell function. Cell Metab. 2020;31:920-936.e927. https://doi.org/10.1016/j.cmet.2020.03.004.CrossRefPubMedPubMedCentral

146.

Torigoe M, et al. l-Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling. Mod Rheumatol. 2019;29:885–91. https://doi.org/10.1080/14397595.2018.1510822.CrossRefPubMed

147.

Jiang S, Yan W, Wang SE, Baltimore D. Let-7 suppresses B cell activation through restricting the availability of necessary nutrients. Cell Metab. 2018;27:393–403. https://doi.org/10.1016/j.cmet.2017.12.007.CrossRefPubMed

148.

van Beek AA, et al. Frontline science: tryptophan restriction arrests B cell development and enhances microbial diversity in WT and prematurely aging Ercc1(-/Delta7) mice. J Leukoc Biol. 2017;101:811–21. https://doi.org/10.1189/jlb.1HI0216-062RR.CrossRefPubMed

149.

Kobayashi T, et al. The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity. 2014;41:375–88. https://doi.org/10.1016/j.immuni.2014.08.011.CrossRefPubMed

150.

Zhang B, et al. B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity. Nature. 2021;599:471–6. https://doi.org/10.1038/s41586-021-04082-1.CrossRefPubMedPubMedCentral

151.

Huang, et al. Cancer-cell-derived GABA promotes beta-catenin-mediated tumour growth and immunosuppression. Nat Cell Biol. 2022;24:230–41. https://doi.org/10.1038/s41556-021-00820-9.CrossRefPubMedPubMedCentral

152.

Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429–57. https://doi.org/10.1146/annurev-immunol-020711-075032.CrossRefPubMed

153.

Mayer CT, et al. The microanatomic segregation of selection by apoptosis in the germinal center. Science (New York, NY). 2017. https://doi.org/10.1126/science.aao2602.CrossRefPubMed

154.

Ye L, et al. mTOR promotes antiviral humoral immunity by differentially regulating CD4 helper T cell and B cell responses. J Virol. 2017. https://doi.org/10.1128/JVI.01653-16.CrossRefPubMedPubMedCentral

155.

Raybuck AL, et al. B cell-intrinsic mTORC1 promotes germinal center-defining transcription factor gene expression, somatic hypermutation, and memory B cell generation in humoral immunity. J Immunol (Baltimore, Md: 1950). 2018;200:2627–39. https://doi.org/10.4049/jimmunol.1701321.CrossRef

156.

Li B, et al. Mammalian target of rapamycin complex 1 signalling is essential for germinal centre reaction. Immunology. 2017;152:276–86. https://doi.org/10.1111/imm.12767.CrossRefPubMedPubMedCentral

157.

Ersching J, et al. Germinal center selection and affinity maturation require dynamic regulation of mTORC1 kinase. Immunity. 2017;46:1045-1058.e1046. https://doi.org/10.1016/j.immuni.2017.06.005.CrossRefPubMedPubMedCentral

158.

Lee K, et al. Requirement for rictor in homeostasis and function of mature B lymphoid cells. Blood. 2013;122:2369–79. https://doi.org/10.1182/blood-2013-01-477505.CrossRefPubMedPubMedCentral

159.

Yang J, et al. Critical roles of mTOR Complex 1 and 2 for T follicular helper cell differentiation and germinal center responses. Elife. 2016. https://doi.org/10.7554/eLife.17936.CrossRefPubMedPubMedCentral

160.

Hao Y, et al. The kinase complex mTOR complex 2 promotes the follicular migration and functional maturation of differentiated follicular helper CD4+ T cells during viral infection. Front Immunol. 2018;9:1127. https://doi.org/10.3389/fimmu.2018.01127.CrossRefPubMedPubMedCentral

161.

Zeng H, et al. mTORC1 and mTORC2 kinase signaling and glucose metabolism drive follicular helper T cell differentiation. Immunity. 2016;45:540–54. https://doi.org/10.1016/j.immuni.2016.08.017.CrossRefPubMedPubMedCentral

162.

Zhou X, et al. Stearoyl-CoA desaturase-mediated monounsaturated fatty acid availability supports humoral immunity. Cell Rep. 2021;34:108601. https://doi.org/10.1016/j.celrep.2020.108601.CrossRefPubMedPubMedCentral

163.

Cho SH, et al. Germinal centre hypoxia and regulation of antibody qualities by a hypoxia response system. Nature. 2016;537:234–8. https://doi.org/10.1038/nature19334.CrossRefPubMedPubMedCentral

164.

Xu L, et al. The kinase mTORC1 promotes the generation and suppressive function of follicular regulatory T cells. Immunity. 2017;47:538-551.e535. https://doi.org/10.1016/j.immuni.2017.08.011.CrossRefPubMed

165.

Yang L, et al. CCL2 regulation of MST1-mTOR-STAT1 signaling axis controls BCR signaling and B-cell differentiation. Cell Death Differ. 2021. https://doi.org/10.1038/s41418-021-00775-2.CrossRefPubMedPubMedCentral

166.

Nagai M, et al. Fasting-refeeding impacts immune cell dynamics and mucosal immune responses. Cell. 2019;178:1072-1087.e1014. https://doi.org/10.1016/j.cell.2019.07.047.CrossRefPubMed

167.

Zheng Z, et al. CXCL13/CXCR5 axis predicts poor prognosis and promotes progression through PI3K/AKT/mTOR pathway in clear cell renal cell carcinoma. Front Oncol. 2018;8:682. https://doi.org/10.3389/fonc.2018.00682.CrossRefPubMed

168.

Helmink BA, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–55. https://doi.org/10.1038/s41586-019-1922-8.CrossRefPubMedPubMedCentral

169.

Petitprez F, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556–60. https://doi.org/10.1038/s41586-019-1906-8.CrossRefPubMed

170.

Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112–7. https://doi.org/10.1002/eji.1830050208.CrossRefPubMed

171.

Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975;16:230–9. https://doi.org/10.1002/ijc.2910160205.CrossRefPubMed

172.

Crinier A, et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. Immunity. 2018;49:971–86. https://doi.org/10.1016/j.immuni.2018.09.009.CrossRefPubMedPubMedCentral

173.

Bjorkstrom NK, Ljunggren HG, Michaelsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016;16:310–20. https://doi.org/10.1038/nri.2016.34.CrossRefPubMed

174.

Vicario M, Amat C, Rivero M, Moreto M, Pelegri C. Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr. 2007;137:1931–7. https://doi.org/10.1093/jn/137.8.1931.CrossRefPubMed

175.

Song QH, et al. Glutamine supplementation and immune function during heavy load training. Int J Clin Pharmacol Ther. 2015;53:372–6. https://doi.org/10.5414/CP202227.CrossRefPubMed

176.

Krzywkowski K, et al. Effect of glutamine supplementation on exercise-induced changes in lymphocyte function. Am J Physiol Cell Physiol. 2001;281:C1259-1265. https://doi.org/10.1152/ajpcell.2001.281.4.C1259.CrossRefPubMed

177.

Wee YM, et al. Tissue-resident natural killer cells exacerbate tubulointerstitial fibrosis by activating transglutaminase 2 and syndecan-4 in a model of aristolochic acid-induced nephropathy. BMB Rep. 2019;52:554–9.CrossRefPubMedPubMedCentral

178.

Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol. 2002;55:221–8. https://doi.org/10.1046/j.1365-3083.2002.01053.x.CrossRefPubMed

179.

Park JE, et al. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2020-000873.CrossRefPubMedPubMedCentral

180.

Zhang M, et al. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci U S A. 2018;115:E10915–24. https://doi.org/10.1073/pnas.1811615115.CrossRefPubMedPubMedCentral

181.

Wang Z, Yin C, Lum LG, Simons A, Weiner GJ. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. J Hematol Oncol. 2021;14:204. https://doi.org/10.1186/s13045-021-01216-w.CrossRefPubMedPubMedCentral

182.

Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200–18. https://doi.org/10.1038/s41573-019-0052-1.CrossRefPubMed

183.

Loftus RM, et al. Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat Commun. 2018;9:2341. https://doi.org/10.1038/s41467-018-04719-2.CrossRefPubMedPubMedCentral

184.

Jensen H, Potempa M, Gotthardt D, Lanier LL. Cutting edge: IL-2-induced expression of the amino acid transporters SLC1A5 and CD98 is a prerequisite for NKG2D-mediated activation of human NK cells. J Immunol (Baltimore, Md: 1950). 2017;199:1967–72. https://doi.org/10.4049/jimmunol.1700497.CrossRef

185.

Almutairi SM, et al. Interleukin-18 up-regulates amino acid transporters and facilitates amino acid-induced mTORC1 activation in natural killer cells. J Biol Chem. 2019;294:4644–55. https://doi.org/10.1074/jbc.RA118.005892.CrossRefPubMedPubMedCentral

186.

Wang F, et al. Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function. Nat Commun. 2018;9:4874. https://doi.org/10.1038/s41467-018-07277-9.CrossRefPubMedPubMedCentral

187.

Yang C, et al. mTORC1 and mTORC2 differentially promote natural killer cell development. Elife. 2018. https://doi.org/10.7554/eLife.35619.CrossRefPubMedPubMedCentral

188.

Choi WM, et al. Metabotropic glutamate receptor 5 in natural killer cells attenuates liver fibrosis by exerting cytotoxicity to activated stellate cells. Hepatology. 2021;74:2170–85. https://doi.org/10.1002/hep.31875.CrossRefPubMed

189.

Hume DA. The mononuclear phagocyte system. Curr Opin Immunol. 2006;18:49–53. https://doi.org/10.1016/j.coi.2005.11.008.CrossRefPubMed

190.

Füger P, et al. Microglia turnover with aging and in an Alzheimer’s model via long-term in vivo single-cell imaging. Nat Neurosci. 2017;20:1371–6. https://doi.org/10.1038/nn.4631.CrossRefPubMed

191.

Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol. 2013;3:785–97. https://doi.org/10.1002/cphy.c120026.CrossRefPubMedPubMedCentral

192.

Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol. 2014;14:81–93. https://doi.org/10.1038/nri3600.CrossRefPubMed

193.

Yao Y, et al. The macrophage-osteoclast axis in osteoimmunity and osteo-related diseases. Front Immunol. 2021;12:664871. https://doi.org/10.3389/fimmu.2021.664871.CrossRefPubMedPubMedCentral

194.

Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9:259–70. https://doi.org/10.1038/nri2528.CrossRefPubMedPubMedCentral

195.

Mossadegh-Keller N, et al. Developmental origin and maintenance of distinct testicular macrophage populations. J Exp Med. 2017;214:2829–41. https://doi.org/10.1084/jem.20170829.CrossRefPubMedPubMedCentral

196.

Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13:433–44. https://doi.org/10.1038/nrd4280.CrossRefPubMed

197.

den Haan JM, Kraal G. Innate immune functions of macrophage subpopulations in the spleen. J Innate Immun. 2012;4:437–45. https://doi.org/10.1159/000335216.CrossRef

198.

Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123–47. https://doi.org/10.1146/annurev-pathmechdis-012418-012718.CrossRefPubMed

199.

Cozzi A, et al. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat. 2006;13:402–8. https://doi.org/10.1111/j.1365-2893.2005.00706.x.CrossRefPubMed

200.

Sun L, et al. The modulatory activity of tryptophan displaying nanodevices on macrophage activation for preventing acute lung injury. Front Immunol. 2021;12:750128. https://doi.org/10.3389/fimmu.2021.750128.CrossRefPubMedPubMedCentral

201.

Cho SJ, et al. Decreased IDO1-dependent tryptophan metabolism in aged lung during influenza. Eur Respir J. 2021. https://doi.org/10.1183/13993003.00443-2020.CrossRefPubMedPubMedCentral

202.

Nishimura M, et al. Upregulated kynurenine pathway enzymes in aortic atherosclerotic aneurysm: macrophage kynureninase downregulates inflammation. J Atheroscler Thromb. 2021;28:1214–40. https://doi.org/10.5551/jat.58248.CrossRefPubMed

203.

Minhas PS, et al. Macrophage de novo NAD(+) synthesis specifies immune function in aging and inflammation. Nat Immunol. 2019;20:50–63. https://doi.org/10.1038/s41590-018-0255-3.CrossRefPubMed

204.

Bosco MC, et al. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and −1 beta in macrophages. J Immunol. 2000;164:3283–91. https://doi.org/10.4049/jimmunol.164.6.3283.CrossRefPubMed

205.

Toulmonde M, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4:93–7. https://doi.org/10.1001/jamaoncol.2017.1617.CrossRefPubMed

206.

Takenaka MC, et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019;22:729–40. https://doi.org/10.1038/s41593-019-0370-y.CrossRefPubMedPubMedCentral

207.

Hezaveh K, et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity. 2022;55:324–40. https://doi.org/10.1016/j.immuni.2022.01.006.CrossRefPubMedPubMedCentral

208.

Panitz V, et al. Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics. 2021;11:9217–33. https://doi.org/10.7150/thno.60679.CrossRefPubMedPubMedCentral

209.

Bonvini A, et al. Effects of different branched-chain amino acids supplementation protocols on the inflammatory response of LPS-stimulated RAW 264.7 macrophages. Amino Acids. 2021;53:597–607. https://doi.org/10.1007/s00726-021-02940-w.CrossRefPubMed

210.

Ko JH, et al. BCAT1 affects mitochondrial metabolism independently of leucine transamination in activated human macrophages. J Cell Sci. 2020. https://doi.org/10.1242/jcs.247957.CrossRefPubMedPubMedCentral

211.

Papathanassiu AE, et al. BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases. Nat Commun. 2017;8:16040. https://doi.org/10.1038/ncomms16040.CrossRefPubMedPubMedCentral

212.

Michelucci A, et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc Natl Acad Sci U S A. 2013;110:7820–5. https://doi.org/10.1073/pnas.1218599110.CrossRefPubMedPubMedCentral

213.

Grajeda-Iglesias C, et al. Leucine supplementation attenuates macrophage foam-cell formation: Studies in humans, mice, and cultured macrophages. BioFactors. 2018;44:245–62. https://doi.org/10.1002/biof.1415.CrossRefPubMed

214.

Wang F, et al. Activation of GCN2 in macrophages promotes white adipose tissue browning and lipolysis under leucine deprivation. FASEB J. 2021;35:e21652. https://doi.org/10.1096/fj.202100061RR.CrossRefPubMed

215.

McKell MC, et al. Promotion of anti-tuberculosis macrophage activity by L-arginine in the absence of nitric oxide. Front Immunol. 2021;12:653571. https://doi.org/10.3389/fimmu.2021.653571.CrossRefPubMedPubMedCentral

216.

Aoki JI, et al. Dual transcriptome analysis reveals differential gene expression modulation influenced by Leishmania arginase and host genetic background. Microb Genom. 2020. https://doi.org/10.1099/mgen.0.000427.CrossRefPubMedPubMedCentral

217.

Granger DL, Hibbs JB Jr, Broadnax LM. Urinary nitrate excretion in relation to murine macrophage activation. Influence of dietary L-arginine and oral NG-monomethyl-L-arginine. J Immunol. 1991;146:1294–302.CrossRefPubMed

218.

Peters H, Border WA, Noble NA. L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kidney Int. 1999;55:2264–73. https://doi.org/10.1046/j.1523-1755.1999.00462.x.CrossRefPubMed

219.

Gillespie JS, Liu XR, Martin W. The effects of L-arginine and NG-monomethyl L-arginine on the response of the rat anococcygeus muscle to NANC nerve stimulation. Br J Pharmacol. 1989;98:1080–2. https://doi.org/10.1111/j.1476-5381.1989.tb12650.x.CrossRefPubMedPubMedCentral

220.

Badirzadeh A, et al. Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites. PLoS Negl Trop Dis. 2017;11:e0005774. https://doi.org/10.1371/journal.pntd.0005774.CrossRefPubMedPubMedCentral

221.

Hannemann N, et al. Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis. J Clin Invest. 2019;129:2669–84. https://doi.org/10.1172/JCI96832.CrossRefPubMedPubMedCentral

222.

Dowling JK, et al. Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophages. Nat Commun. 2021;12:1460. https://doi.org/10.1038/s41467-021-21617-2.CrossRefPubMedPubMedCentral

223.

Lasch M, et al. Arginase inhibition attenuates arteriogenesis and interferes with M2 macrophage accumulation. Lab Invest. 2016;96:830–8. https://doi.org/10.1038/labinvest.2016.62.CrossRefPubMed

224.

Gotoh T, Mori M. Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells. J Cell Biol. 1999;144:427–34. https://doi.org/10.1083/jcb.144.3.427.CrossRefPubMedPubMedCentral

225.

MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323–50. https://doi.org/10.1146/annurev.immunol.15.1.323.CrossRefPubMed

226.

Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol (Baltimore, Md: 1950). 1998;160:5347–54.CrossRef

227.

Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol. 1995;25:1101–4. https://doi.org/10.1002/eji.1830250436.CrossRefPubMed

228.

Yeramian A, et al. Arginine transport via cationic amino acid transporter 2 plays a critical regulatory role in classical or alternative activation of macrophages. J Immunol. 2006;176:5918–24. https://doi.org/10.4049/jimmunol.176.10.5918.CrossRefPubMed

229.

Yeramian A, et al. Macrophages require distinct arginine catabolism and transport systems for proliferation and for activation. Eur J Immunol. 2006;36:1516–26. https://doi.org/10.1002/eji.200535694.CrossRefPubMed

230.

Nicholson B, Manner CK, Kleeman J, MacLeod CL. Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. J Biol Chem. 2001;276:15881–5. https://doi.org/10.1074/jbc.M010030200.CrossRefPubMed

231.

Ji L, et al. Slc6a8-mediated creatine uptake and accumulation reprogram macrophage polarization via regulating cytokine responses. Immunity. 2019;51:272–84. https://doi.org/10.1016/j.immuni.2019.06.007.CrossRefPubMed

232.

Zheng X, et al. Correction of arginine metabolism with sepiapterin-the precursor of nitric oxide synthase cofactor BH4-induces immunostimulatory-shift of breast cancer. Biochem Pharmacol. 2020;176:113887. https://doi.org/10.1016/j.bcp.2020.113887.CrossRefPubMedPubMedCentral

233.

Jha AK, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42:419–30. https://doi.org/10.1016/j.immuni.2015.02.005.CrossRefPubMed

234.

Liu PS, et al. alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18:985–94. https://doi.org/10.1038/ni.3796.CrossRefPubMed

235.

Koenis DS, et al. Nuclear receptor Nur77 limits the macrophage inflammatory response through transcriptional reprogramming of mitochondrial metabolism. Cell Rep. 2018;24:2127–40. https://doi.org/10.1016/j.celrep.2018.07.065.CrossRefPubMedPubMedCentral

236.

Hou YC, et al. Protective effects of glutamine and leucine supplementation on sepsis-induced skeletal muscle injuries. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms222313003.CrossRefPubMedPubMedCentral

237.

Fernandez-Bustamante A, et al. Brief glutamine pretreatment increases alveolar macrophage CD163/heme oxygenase-1/p38-MAPK dephosphorylation pathway and decreases capillary damage but not neutrophil recruitment in IL-1/LPS-insufflated rats. PLoS ONE. 2015;10:e0130764. https://doi.org/10.1371/journal.pone.0130764.CrossRefPubMedPubMedCentral

238.

Merlin J, et al. Non-canonical glutamine transamination sustains efferocytosis by coupling redox buffering to oxidative phosphorylation. Nat Metab. 2021;3:1313–26. https://doi.org/10.1038/s42255-021-00471-y.CrossRefPubMedPubMedCentral

239.

Sartori T, et al. Effects of glutamine, taurine and their association on inflammatory pathway markers in macrophages. Inflammopharmacology. 2018;26:829–38. https://doi.org/10.1007/s10787-017-0406-4.CrossRefPubMed

240.

Rogero MM, et al. Dietary glutamine supplementation affects macrophage function, hematopoiesis and nutritional status in early weaned mice. Clin Nutr. 2008;27:386–97. https://doi.org/10.1016/j.clnu.2008.03.004.CrossRefPubMed

241.

He L, Weber KJ, Schilling JD. Glutamine modulates macrophage lipotoxicity. Nutrients. 2016;8:215. https://doi.org/10.3390/nu8040215.CrossRefPubMedPubMedCentral

242.

Fu Q, et al. Tumor-associated macrophage-derived interleukin-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2019;75:752–63. https://doi.org/10.1016/j.eururo.2018.09.030.CrossRefPubMed

243.

Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137:1142–62. https://doi.org/10.1084/jem.137.5.1142.CrossRefPubMedPubMedCentral

244.

Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. 2014;40:642–56. https://doi.org/10.1016/j.immuni.2014.04.016.CrossRefPubMed

245.

Reizis B. Plasmacytoid dendritic cells: development regulation and function. Immunity 2019:50(1):37–50. https://doi.org/10.1016/j.immuni.2018.12.027CrossRefPubMedPubMedCentral

246.

Goudot C, et al. Aryl hydrocarbon receptor controls monocyte differentiation into dendritic cells versus macrophages. Immunity. 2017;47:582-596.e586. https://doi.org/10.1016/j.immuni.2017.08.016.CrossRefPubMed

247.

Oshi M, et al. Plasmacytoid dendritic cell (pDC) infiltration correlate with tumor infiltrating lymphocytes, cancer immunity, and better survival in triple negative breast cancer (TNBC) more strongly than conventional dendritic cell (cDC). Cancers. 2020. https://doi.org/10.3390/cancers12113342.CrossRefPubMedPubMedCentral

248.

Riemann D, et al. Blood immune cell biomarkers in lung cancer. Clin Exp Immunol. 2019;195:179–89. https://doi.org/10.1111/cei.13219.CrossRefPubMed

249.

Poropatich K, et al. OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity. J Clin Investig. 2020;130:3528–42. https://doi.org/10.1172/JCI131992.CrossRefPubMedPubMedCentral

250.

Labidi-Galy SI, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Can Res. 2011;71:5423–34. https://doi.org/10.1158/0008-5472.CAN-11-0367.CrossRef

251.

Chow KV, Lew AM, Sutherland RM, Zhan Y. Monocyte-derived dendritic cells promote Th polarization, whereas conventional dendritic cells promote Th proliferation. J Immunol (Baltimore, Md: 1950). 2016;196:624–36. https://doi.org/10.4049/jimmunol.1501202.CrossRef

252.

Plantinga M, et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity. 2013;38:322–35. https://doi.org/10.1016/j.immuni.2012.10.016.CrossRefPubMed

253.

Stamper CC, et al. Crystal structure of the B7–1/CTLA-4 complex that inhibits human immune responses. Nature. 2001;410:608–11. https://doi.org/10.1038/35069118.CrossRefPubMed

254.

Peng Q, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11:4835. https://doi.org/10.1038/s41467-020-18570-x.CrossRefPubMedPubMedCentral

255.

Li C, et al. Mechanism of indoleamine 2, 3-dioxygenase inhibiting cardiac allograft rejection in mice. J Cell Mol Med. 2020;24:3438–48. https://doi.org/10.1111/jcmm.15024.CrossRefPubMedPubMedCentral

256.

Liu Z, et al. Suppression of memory CD8 T cell generation and function by tryptophan catabolism. J Immunol. 2007;178:4260–6. https://doi.org/10.4049/jimmunol.178.7.4260.CrossRefPubMed

257.

Mondanelli G, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity. 2017;46:233–44. https://doi.org/10.1016/j.immuni.2017.01.005.CrossRefPubMedPubMedCentral

258.

Tashita C, et al. Kynurenine plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice. World J Gastroenterol. 2020;26:918–32. https://doi.org/10.3748/wjg.v26.i9.918.CrossRefPubMedPubMedCentral

259.

Lee WS, et al. The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. Int Immunopharmacol. 2013;17:721–6. https://doi.org/10.1016/j.intimp.2013.08.018.CrossRefPubMed

260.

Romani L, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108:2265–74. https://doi.org/10.1182/blood-2006-02-004762.CrossRefPubMed

261.

Chalise JP, et al. IDO1 and TGF-beta mediate protective effects of IFN-alpha in antigen-induced arthritis. J Immunol. 2016;197:3142–51. https://doi.org/10.4049/jimmunol.1502125.CrossRefPubMedPubMedCentral

262.

Ghimire S, et al. Indoxyl 3-sulfate inhibits maturation and activation of human monocyte-derived dendritic cells. Immunobiology. 2018;223:239–45. https://doi.org/10.1016/j.imbio.2017.10.014.CrossRefPubMed

263.

George MM, Subramanian Vignesh K, Landero Figueroa JA, Caruso JA, Deepe GS Jr. Zinc induces dendritic cell tolerogenic phenotype and skews regulatory T cell-Th17 balance. J Immunol. 2016;197:1864–76. https://doi.org/10.4049/jimmunol.1600410.CrossRefPubMed

264.

Sharma MD, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Investig. 2007;117:2570–82. https://doi.org/10.1172/JCI31911.CrossRefPubMedPubMedCentral

265.

Fallarino F, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4:1206–12. https://doi.org/10.1038/ni1003.CrossRefPubMed

266.

Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57. https://doi.org/10.1186/s12943-018-0779-z.CrossRefPubMedPubMedCentral

267.

Gunderson AJ, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 2016;6:270–85. https://doi.org/10.1158/2159-8290.CD-15-0827.CrossRefPubMed

268.

Stiff A, et al. Myeloid-derived suppressor cells express bruton’s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res. 2016;76:2125–36. https://doi.org/10.1158/0008-5472.CAN-15-1490.CrossRefPubMedPubMedCentral

269.

Singhal E, Kumar P, Sen P. A novel role for Bruton’s tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells. J Biol Chem. 2011;286:32054–63. https://doi.org/10.1074/jbc.M111.271247.CrossRefPubMedPubMedCentral

270.

Kawakami Y, et al. Regulation of dendritic cell maturation and function by Bruton’s tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci U S A. 2006;103:153–8. https://doi.org/10.1073/pnas.0509784103.CrossRefPubMed

271.

Sharma MD, et al. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. Immunity. 2021;54:2354–71. https://doi.org/10.1016/j.immuni.2021.09.005.CrossRefPubMedPubMedCentral

272.

Zhong K, et al. Murine myeloid dendritic cells that phagocytose apoptotic T cells inhibit the immune response via NO. PLoS ONE. 2012;7:e49378. https://doi.org/10.1371/journal.pone.0049378.CrossRefPubMedPubMedCentral

273.

Liu H, et al. Differential nitric oxide induced by Mycobacterium bovis and BCG leading to dendritic cells apoptosis in a caspase dependent manner. Microb Pathog. 2020;149:104303. https://doi.org/10.1016/j.micpath.2020.104303.CrossRefPubMed

274.

Bhatt S, et al. All-trans retinoic acid induces arginase-1 and inducible nitric oxide synthase-producing dendritic cells with T cell inhibitory function. J Immunol. 2014;192:5098–108. https://doi.org/10.4049/jimmunol.1303073.CrossRefPubMed

275.

Panfili E, et al. IL-35Ig-expressing dendritic cells induce tolerance via Arginase 1. J Cell Mol Med. 2019;23:3757–61. https://doi.org/10.1111/jcmm.14215.CrossRefPubMedPubMedCentral

276.

Fossati-Jimack L, et al. Intranasal peptide-induced tolerance and linked suppression: consequences of complement deficiency. Immunology. 2015;144:149–57. https://doi.org/10.1111/imm.12358.CrossRefPubMed

277.

Simioni PU, Fernandes LG, Tamashiro WM. Downregulation of L-arginine metabolism in dendritic cells induces tolerance to exogenous antigen. Int J Immunopathol Pharmacol. 2017;30:44–57. https://doi.org/10.1177/0394632016678873.CrossRefPubMedPubMedCentral

278.

Gabrilovich DI, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:425. https://doi.org/10.1158/0008-5472.CAN-06-3037.CrossRefPubMedPubMedCentral

279.

Mandruzzato S, et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother. 2016;65:161–9. https://doi.org/10.1007/s00262-015-1782-5.CrossRefPubMedPubMedCentral

280.

Roussel M, et al. Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow. J Leukoc Biol. 2017;102:437–47. https://doi.org/10.1189/jlb.5MA1116-457R.CrossRefPubMedPubMedCentral

281.

Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity. Immunity. 2021;54:875–84. https://doi.org/10.1016/j.immuni.2021.04.004.CrossRefPubMedPubMedCentral

282.

Darcy CJ, et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care. 2014;18:R163. https://doi.org/10.1186/cc14003.CrossRefPubMedPubMedCentral

283.

Brodaczewska KK, Donskow-Łysoniewska K, Krawczak K, Doligalska M. Role of l-arginine and CD11b+Gr-1+ cells in immunosuppression induced by Heligmosomoides polygyrus bakeri. Parasite Immunol. 2020;42:e12704. https://doi.org/10.1111/pim.12704.CrossRefPubMed

284.

Pallett LJ, et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med. 2015;21:591–600. https://doi.org/10.1038/nm.3856.CrossRefPubMedPubMedCentral

285.

Miret JJ, et al. Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity. J Immunother Cancer. 2019;7:32. https://doi.org/10.1186/s40425-019-0504-5.CrossRefPubMedPubMedCentral

286.

Rodriguez PC, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Can Res. 2009;69:1553–60. https://doi.org/10.1158/0008-5472.CAN-08-1921.CrossRef

287.

Cimen Bozkus C, Elzey BD, Crist SA, Ellies LG, Ratliff TL. Expression of cationic amino acid transporter 2 is required for myeloid-derived suppressor cell-mediated control of T cell immunity. J Immunol (Baltimore, Md: 1950). 2015;195:5237–50. https://doi.org/10.4049/jimmunol.1500959.CrossRef

288.

Bian Z, et al. Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation. Eur J Immunol. 2018;48:1046–58. https://doi.org/10.1002/eji.201747355.CrossRefPubMedPubMedCentral

289.

Maeda A, et al. Monocytic MDSCs regulate macrophage-mediated xenogenic cytotoxicity. Transpl Immunol. 2015;33:140–5. https://doi.org/10.1016/j.trim.2015.07.002.CrossRefPubMed

290.

Yu J, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (Baltimore, Md:1950). 2013;190:3783–97. https://doi.org/10.4049/jimmunol.1201449.CrossRef

291.

Li A, et al. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett. 2018;431:54–63. https://doi.org/10.1016/j.canlet.2018.05.005.CrossRefPubMedPubMedCentral

292.

Ozturk S, Kalter V, Roessner PM, Sunbul M, Seiffert M. IDO1-targeted therapy does not control disease development in the emicro-TCL1 mouse model of chronic lymphocytic leukemia. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13081899.CrossRefPubMedPubMedCentral

293.

Tousif S, et al. Indoleamine 2, 3-dioxygenase promotes aryl hydrocarbon receptor-dependent differentiation of regulatory B cells in lung cancer. Front Immunol. 2021;12:747780. https://doi.org/10.3389/fimmu.2021.747780.CrossRefPubMedPubMedCentral

294.

Oh M-H, et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Investig. 2020;130:3865–84. https://doi.org/10.1172/JCI131859.CrossRefPubMedPubMedCentral

295.

Dey S, et al. IDO1 signaling through GCN2 in a subpopulation of Gr-1(+) cells shifts the IFNgamma/IL6 balance to promote neovascularization. Cancer Immunol Res. 2021;9:514–28. https://doi.org/10.1158/2326-6066.CIR-20-0226.CrossRefPubMed

296.

Sun H-W, et al. Glutamine deprivation promotes the generation and mobilization of MDSCs by enhancing expression of G-CSF and GM-CSF. Front Immunol. 2020;11:616367. https://doi.org/10.3389/fimmu.2020.616367.CrossRefPubMed

297.

Hammami I, Chen J, Bronte V, DeCrescenzo G, Jolicoeur M. L-glutamine is a key parameter in the immunosuppression phenomenon. Biochem Biophys Res Commun. 2012;425:724–9. https://doi.org/10.1016/j.bbrc.2012.07.139.CrossRefPubMed

298.

Zhang C, et al. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury. Cell Death Dis. 2017;8:e2695. https://doi.org/10.1038/cddis.2017.86.CrossRefPubMedPubMedCentral

299.

Halaby MJ, et al. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. Sci Immunol. 2019. https://doi.org/10.1126/sciimmunol.aax8189.CrossRefPubMedPubMedCentral

300.

Chitapanarux I, et al. Arginine, glutamine, and fish oil supplementation in cancer patients treated with concurrent chemoradiotherapy: a randomized control study. Curr Probl Cancer. 2020;44:100482. https://doi.org/10.1016/j.currproblcancer.2019.05.005.CrossRefPubMed

301.

Sittitrai P, Ruenmarkkaew D, Booyaprapa S, Kasempitakpong B. Effect of a perioperative immune-enhancing diet in clean-contaminated head and neck cancer surgery: a randomized controlled trial. Int J Surg. 2021;93:106051. https://doi.org/10.1016/j.ijsu.2021.106051.CrossRefPubMed

302.

Cao Y, et al. l-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice. Int Immunopharmacol. 2016;35:7–14. https://doi.org/10.1016/j.intimp.2016.03.002.CrossRefPubMed

303.

Satoh Y, et al. Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy. Cancer Sci. 2020;111:2248–58. https://doi.org/10.1111/cas.14490.CrossRefPubMedPubMedCentral

304.

Cao Y, Feng Y, Zhang Y, Zhu X, Jin F. L-arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo. BMC Cancer. 2016;16:343. https://doi.org/10.1186/s12885-016-2376-0.CrossRefPubMedPubMedCentral

305.

Szefel J, et al. The effect of l-arginine supplementation and surgical trauma on the frequency of myeloid-derived suppressor cells and T lymphocytes in tumour and blood of colorectal cancer patients. Adv Med Sci. 2022;67:66–78. https://doi.org/10.1016/j.advms.2021.12.005.CrossRefPubMed

306.

Wang R, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35:871–82. https://doi.org/10.1016/j.immuni.2011.09.021.CrossRefPubMedPubMedCentral

307.

Yue M, Jiang J, Gao P, Liu H, Qing G. Oncogenic MYC activates a feedforward regulatory loop promoting essential amino acid metabolism and tumorigenesis. Cell Rep. 2017;21:3819–32. https://doi.org/10.1016/j.celrep.2017.12.002.CrossRefPubMed

308.

Verbist KC, et al. Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature. 2016;532:389–93. https://doi.org/10.1038/nature17442.CrossRefPubMedPubMedCentral

309.

Liu P, et al. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017;66:167–81. https://doi.org/10.1002/hep.29183.CrossRefPubMed

310.

Park Y, Reyna-Neyra A, Philippe L, Thoreen CC. mTORC1 balances cellular amino acid supply with demand for protein synthesis through post-transcriptional control of ATF4. Cell Rep. 2017;19:1083–90. https://doi.org/10.1016/j.celrep.2017.04.042.CrossRefPubMedPubMedCentral

311.

Li S, et al. miR-31-5p regulates type I interferon by targeting SLC15A4 in plasmacytoid dendritic cells of systemic lupus erythematosus. J Inflamm Res. 2022;15:6607–16. https://doi.org/10.2147/JIR.S383623.CrossRefPubMedPubMedCentral

312.

Morotti M, et al. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proc Natl Acad Sci USA. 2019;116:12452–61. https://doi.org/10.1073/pnas.1818521116.CrossRefPubMedPubMedCentral

313.

Elorza A, et al. HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell. 2012;48:681–91. https://doi.org/10.1016/j.molcel.2012.09.017.CrossRefPubMed

314.

Luu TT, et al. IL-15 and CD155 expression regulate LAT expression in murine DNAM1+ NK cells, enhancing their effectors functions. Eur J Immunol. 2020;50:494–504. https://doi.org/10.1002/eji.201948233.CrossRefPubMed

315.

Czuba LC, Hillgren KM, Swaan PW. Post-translational modifications of transporters. Pharmacol Ther. 2018;192:88–99. https://doi.org/10.1016/j.pharmthera.2018.06.013.CrossRefPubMedPubMedCentral

316.

Liu E, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32:520–31. https://doi.org/10.1038/leu.2017.226.CrossRefPubMed

317.

Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Investig. 2021. https://doi.org/10.1172/JCI140100.CrossRefPubMedPubMedCentral

318.

Cormerais Y, et al. Genetic disruption of the multifunctional CD98/LAT1 complex demonstrates the key role of essential amino acid transport in the control of mTORC1 and tumor growth. Can Res. 2016;76:4481–92. https://doi.org/10.1158/0008-5472.CAN-15-3376.CrossRef

319.

Hayes GM, et al. Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015;137:710–20. https://doi.org/10.1002/ijc.29415.CrossRefPubMedPubMedCentral

320.

Dolšak A, Gobec S, Sova M. Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets. Pharmacol Ther. 2021;221:107746. https://doi.org/10.1016/j.pharmthera.2020.107746.CrossRefPubMed

321.

Mullard A. IDO takes a blow. Nat Rev Drug Discov. 2018;17:307. https://doi.org/10.1038/nrd.2018.67.CrossRefPubMed

322.

Feng X, Shen P, Wang Y, Li Z, Bian J. Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO. Biochem Pharmacol. 2019;168:214–23. https://doi.org/10.1016/j.bcp.2019.07.011.CrossRefPubMed

323.

Liang H, et al. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer. Cancer Lett. 2021;522:32–43. https://doi.org/10.1016/j.canlet.2021.09.012.CrossRefPubMed

324.

Naing A, et al. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2020-000870.CrossRefPubMedPubMedCentral

325.

Yang D, et al. N-Benzyl/Aryl substituted tryptanthrin as dual inhibitors of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase. J Med Chem. 2019;62:9161–74. https://doi.org/10.1021/acs.jmedchem.9b01079.CrossRefPubMed

326.

Yang L, et al. 4,6-substituted-1H-indazoles as potent IDO1/TDO dual inhibitors. Bioorg Med Chem. 2019;27:1087–98. https://doi.org/10.1016/j.bmc.2019.02.014.CrossRefPubMed

327.

Schramme F, et al. Inhibition of tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors. Cancer Immunol Res. 2020;8:32–45. https://doi.org/10.1158/2326-6066.CIR-19-0041.CrossRefPubMed

328.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389–402. https://doi.org/10.1084/jem.20130066.CrossRefPubMedPubMedCentral

329.

Wainwright DA, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20:5290–301. https://doi.org/10.1158/1078-0432.CCR-14-0514.CrossRefPubMedPubMedCentral

330.

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9. https://doi.org/10.1038/nm1196.CrossRefPubMed

331.

Berrong Z, et al. Antigen-specific antitumor responses induced by OX40 agonist are enhanced by the IDO inhibitor indoximod. Cancer Immunol Res. 2018;6:201–8. https://doi.org/10.1158/2326-6066.CIR-17-0223.CrossRefPubMed

332.

Zang X, Song J, Yi X, Piyu J. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer. J Mater Chem B. 2022;10:2019–27. https://doi.org/10.1039/d2tb00197g.CrossRefPubMed

333.

Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med. 2018;24:194–202. https://doi.org/10.1038/nm.4464.CrossRefPubMedPubMedCentral

334.

Qin R, et al. Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2021-002840.CrossRefPubMedPubMedCentral

335.

Ray A, et al. Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2020;34:567–77. https://doi.org/10.1038/s41375-019-0558-x.CrossRefPubMed

336.

Cronin SJF, et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature. 2018;563:564–8. https://doi.org/10.1038/s41586-018-0701-2.CrossRefPubMedPubMedCentral

337.

Triplett TA, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol. 2018;36:758–64. https://doi.org/10.1038/nbt.4180.CrossRefPubMedPubMedCentral

338.

Steggerda SM, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017;5:101. https://doi.org/10.1186/s40425-017-0308-4.CrossRefPubMedPubMedCentral

339.

Czystowska-Kuzmicz M, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10:3000. https://doi.org/10.1038/s41467-019-10979-3.CrossRefPubMedPubMedCentral

340.

Mitcheltree MJ, et al. Discovery and optimization of rationally designed bicyclic inhibitors of human arginase to enhance cancer immunotherapy. ACS Med Chem Lett. 2020;11:582–8. https://doi.org/10.1021/acsmedchemlett.0c00058.CrossRefPubMedPubMedCentral

341.

Gao W, et al. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells. J Immunother Cancer. 2019;7:231. https://doi.org/10.1186/s40425-019-0676-z.CrossRefPubMedPubMedCentral

342.

Gehad AE, et al. Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J Invest Dermatol. 2012;132:2642–51. https://doi.org/10.1038/jid.2012.190.CrossRefPubMedPubMedCentral

343.

Udumula MP, et al. Ovarian cancer modulates the immunosuppressive function of CD11b(+)Gr1(+) myeloid cells via glutamine metabolism. Mol Metab. 2021;53:101272. https://doi.org/10.1016/j.molmet.2021.101272.CrossRefPubMedPubMedCentral

344.

Lee JE, Safe S. 3ʹ,4ʹ-dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells. Toxicol Sci. 2000;58:235–42. https://doi.org/10.1093/toxsci/58.2.235.CrossRefPubMed

345.

Shi J, et al. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy. J Immunother Cancer. 2019;7:246. https://doi.org/10.1186/s40425-019-0725-7.CrossRefPubMedPubMedCentral

346.

Shinde R, et al. Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. Nat Immunol. 2018;19:571–82. https://doi.org/10.1038/s41590-018-0107-1.CrossRefPubMedPubMedCentral

347.

Schmidt S, et al. A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nat Cell Biol. 2019;21:1413–24. https://doi.org/10.1038/s41556-019-0408-0.CrossRefPubMedPubMedCentral

348.

Nakamura A, et al. Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response. Proc Natl Acad Sci USA. 2018;115:E7776–85. https://doi.org/10.1073/pnas.1805523115.CrossRefPubMedPubMedCentral

349.

Jiangbin Y, et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 2010;29(12):2082–96.CrossRef

350.

Morikawa N, et al. LY341495, an mGluR2/3 antagonist, regulates the immunosuppressive function of myeloid-derived suppressor cells and inhibits melanoma tumor growth. Biol Pharm Bull. 2018;41:1866–9. https://doi.org/10.1248/bpb.b18-00055.CrossRefPubMed

2024 ASCO Annual Meeting

Springer Medicine

Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy

Abstract

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Highlights of the Day: Gynecologic cancer

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Neoadjuvant dual immunotherapy improves melanoma outcomes

» View more highlights on the ASCO 2024 congress hub page

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Ten years of ruxolitinib for myelofibrosis: a review of safety

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma

Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain